Everolimus is an mTOR inhibitor, which is believed to inactivate the mTOR pathway dependent by the merlin loss of function [142, 143], while erlotinib is an oral EGFR-Ras-ERK inhibitor, targeting the tumor proliferation [144]. Here, MTOR is linked to neoplasm.